世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000032849

帯状疱疹(帯状ヘルペス)治療薬開発市場:開発段階別、標的別、作用機序別、投与経路別、分子タイプ別、主要企業別(2022年度版)

Global Markets Direct

Herpes Zoster (Shingles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

発刊日 2022/06/30

言語英語

体裁PDF/86ページ

ライセンス/価格86ページ

0000032849

Single
Site
Enterprisewide (Global Site)

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

本レポートは、帯状疱疹(帯状ヘルペス)(感染症)のパイプラインの概要を提供します。

帯状疱疹(帯状ヘルペス)は、痛みを伴う水疱性の皮疹です。水痘・帯状疱疹ウイルスによって引き起こされます。症状としては、発熱や悪寒、頭痛、関節痛、腺の腫れなどがあります。素因は、年齢や免疫力の低下などです。治療には、抗ヒスタミン剤や鎮痛薬などが用いられます。

注)パイプラインガイドの一部のコンテンツ/セクションは、データの入手可能性と関連性に基づいて削除または変更される場合があります。

調査範囲

  • 帯状疱疹(帯状ヘルペス)治療薬の世界的な治療状況についてのスナップショットを提供します。
  • 企業や業界固有の情報源から得た情報に基づいて、企業や大学・研究機関が開発中の帯状疱疹(帯状ヘルペス)治療薬のパイプラインをレビューしています。
  • 登録前から創薬、未公開段階までの様々な開発段階のパイプライン製品をカバーしています。
  • 本レポートでは、パイプライン製品について、製品の説明、ライセンスおよび共同研究の詳細、研究開発の概要、作用機序(MoA)やその他の開発活動を含む、治療薬プロファイルを提供します。
  • 帯状疱疹(帯状ヘルペス)治療薬に関わる主要企業をレビューし、その主要および小規模プロジェクトをすべて掲載します。
  • 作用機序(MoA)、薬物標的、投与経路(RoA)、および分子タイプに基づいて、帯状疱疹(帯状ヘルペス)治療薬を評価します。
  • すべての休止中および中止されたパイプラインプロジェクトを要約します。
  • 帯状疱疹(帯状ヘルペス)を標的としたパイプライン治療薬に関連する最新のニュースをレビューします。

レポート詳細

目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Herpes Zoster (Shingles) - Overview
Herpes Zoster (Shingles) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Herpes Zoster (Shingles) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
Herpes Zoster (Shingles) - Drug Profiles
Herpes Zoster (Shingles) - Dormant Projects
Herpes Zoster (Shingles) - Discontinued Products
Herpes Zoster (Shingles) - Product Development Milestones
Featured News & Press Releases
May 16, 2022: NanoViricides reports update on Shingles drug
Jan 07, 2022: Adjuvance Technologies announces issuance of U.S. patent covering semi-synthetic saponin adjuvants
Mar 30, 2021: Curevo Vaccine announces the approval to conduct a phase 1b clinical trial in South Africa to evaluate safety and immunogenicity of its adjuvanted subunit investigational vaccine, CRV-101, against varicella (Chickenpox) in HIV-positive children
Sep 15, 2020: Curevo Vaccine announces robust antibody response results of Phase I clinical trial of investigational vaccine for Shingles CRV-101
May 14, 2020: NanoViricides provides update on drug candidate NV-HHV-101
Jan 09, 2020: NanoViricides successfully completes required genetic toxicology testing of lead Drug candidate NV-HHV-101
Jan 07, 2020: NanoViricides has initiated genetic toxicology testing required for an IND for its drug candidate
Dec 06, 2019: NanoViricides annual meeting of shareholders to be held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT
Dec 03, 2019: NanoViricides founder Dr. Diwan provides $2,000,000 loan commitment to the company
Dec 02, 2019: NanoViricides has initiated required safety pharmacology assessment of lead drug candidate towards IND
Nov 19, 2019: NanoViricides files quarterly report for period ending September 30, 2019 - HerpeCide drug candidate ind enabling studies update, progressing towards clinical trials
Oct 31, 2019: NanoViricides initiates required dermal sensitization and ocular irritation testing of lead drug candidate towards IND
Oct 09, 2019: NanoViricides has initiated bio-analytical studies as part of IND-enabling safety and toxicology studies of lead candidate NV-HHV-101
Oct 03, 2019: NanoViricides is creating nanomedicines to develop antiviral therapies to combat shingles and herpes viruses
Sep 26, 2019: Curevo Vaccine announces interim results of phase I clinical trial of CRV-101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Herpes Zoster (Shingles), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Herpes Zoster (Shingles) - Pipeline by Adjuvance Technologies Inc, 2022
Herpes Zoster (Shingles) - Pipeline by AIM Vaccine Co Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by Amytrx Therapeutics Inc, 2022
Herpes Zoster (Shingles) - Pipeline by Beijing Green Bamboo Biotechnology Co Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by Beijing Northland Biotech Co Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by BioNTech SE, 2022
Herpes Zoster (Shingles) - Pipeline by CanSino Biologics Inc, 2022
Herpes Zoster (Shingles) - Pipeline by CHA Vaccine Institute Co Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by Chengdu Maikekang BioTechnology Co Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by China National Pharmaceutical Group Corp, 2022
Herpes Zoster (Shingles) - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by CPL Biologicals Pvt Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by Dynavax Technologies Corp, 2022
Herpes Zoster (Shingles) - Pipeline by EyeGene Inc, 2022
Herpes Zoster (Shingles) - Pipeline by GC Biopharma Corp, 2022
Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, 2022
Herpes Zoster (Shingles) - Pipeline by GreenLight Biosciences Holdings PBC, 2022
Herpes Zoster (Shingles) - Pipeline by GSK plc, 2022
Herpes Zoster (Shingles) - Pipeline by Jiangsu Recbio Technology Co Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, 2022
Herpes Zoster (Shingles) - Pipeline by Shanghai Yidao Biological Technology Co Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by Shulov Innovative Science Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by SK Bioscience Ltd, 2022
Herpes Zoster (Shingles) - Pipeline by Vaccitech Plc, 2022
Herpes Zoster (Shingles) - Pipeline by Vapogenix Inc, 2022
Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, 2022
Herpes Zoster (Shingles) - Dormant Projects, 2022
Herpes Zoster (Shingles) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Herpes Zoster (Shingles), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

この商品のレポートナンバー

0000032849

TOP